Skip directly to page options Skip directly to A-Z link

Volume 25, Number 7—July 2019

CME ACTIVITY - Synopsis

Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001–2013

Sarah K. BrodeComments to Author , Hannah Chung, Michael A. Campitelli, Jeffrey C. Kwong, Alex Marchand-Austin, Kevin L. Winthrop, Frances B. Jamieson, and Theodore K. Marras
Author affiliations: West Park Healthcare Centre, Toronto, Ontario, Canada (S.K. Brode); ICES, Toronto (S.K. Brode, H. Chung, M.A. Campitelli, J.C. Kwong); University of Toronto, Toronto (S.K. Brode, J.C. Kwong, F.B. Jamieson, T.K. Marras); University Health Network and Sinai Health System, Toronto (S.K. Brode, T.K. Marras); Toronto Western Family Health Team, Toronto (J.C. Kwong); Public Health Ontario, Toronto (J.C. Kwong, A. Marchand-Austin, F.B. Jamieson); Oregon Health and Science University, Portland, Oregon, USA (K.L. Winthrop)

Main Article

Table 3

Initial treatment regimen, by prescriber specialty, for 688 patients with Mycobacterium avium complex pulmonary disease, Ontario, Canada, 2001–2013*

Regimen Specialty, no. (%) patients
Respirology, n = 383 (55.7) ID, n = 69 (10.0) GIM, n = 51 (7.4) FP/GP, n = 85 (12.3) Other/unknown, n = 100 (14.5)
Standard triple therapy 166 (43.3) 37 (53.6) 22 (43.1) 34 (40.0) 31 (31.0)
Macrolide monotherapy 55 (14.4) 7 (10.1) <5 (≤9.8) 14 (16.5) 15 (15.0)
Macrolide + rifamycin or fluoroquinolone 38 (9.9) ≤5 (≤7.2) ≤5 (<9.8) 6 (7.1) 8 (8.0)
Other 124 (32.4) 20–25 (29.0–36.1) 20 (39.2) 31 (36.5) 46 (46.0)

*Includes the regimen dispensed for at least the first 60 d of treatment. According to privacy regulations, values representing<6 persons are reported as <5, and data are presented as a range of values for categorical variables where back-calculation is possible. GIM, general internal medicine; FP/GP, family practice/general practice; ID, infectious diseases.

Main Article

Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external